Therefore, JNJ0966, the highly selective compound, was used to treat ccRCC cells at the concentration of 10 μM for 24 h in our current study for MMP9 activity inhibition 22, 23. The gene discussed is MMP9; the disease is nonpapillary renal cell carcinoma.